Izeltabart

Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. Izeltabart is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21-C, a linker-payload that combines a Maytansinoid microtubule-disrupting payload with a stable tripeptide linker, at a drug antibody ratio of approximately 2.0. Izeltabart exhibits cytotoxicity toward ADAM9-positive human tumor cell lines and has potent antitumor activity in xenograft tumor models[1].

Research Areas >> Cancer

[1]. Juniper A Scribner, et al. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059.